CONCLUSION
Based on our first review of the data it does not appear unreasonable to assume a link
between the favourable changes in radiographic evidence, favourable changes in
biomarkers and the clinical outcomes achieved by participants in the trial. The clinical data
continues to be highly supportive of the company’s ongoing efforts in the clinic as well as
potential development partners
Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study, page-135
-
- There are more pages in this discussion • 252 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
-0.005(2.38%) |
Mkt cap ! $71.73M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 21.0¢ | 20.0¢ | $152.8K | 744.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 78174 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 84426 | 5 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |